The recent approval of two immune checkpoint inhibitors for the treatment of malignant
melanoma has sparked great interest by physicians and basic scientists searching for novel …

Background & Aims No adjuvant therapy has been shown to extend the survival of patients
with hepatocellular carcinoma (HCC) receiving curative treatment. We investigated whether …

Macrophages are a major component of the leukocyte infiltrate of tumors and play a pivotal
role in the progression of hepatocellular carcinoma (HCC). However, the molecular …

Background Hepatocellular carcinoma (HCC) is a typical inflammation-associated cancer,
but may also provoke antitumour immune responses whose significance and underlying …

Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related death
globally. Above well-known risk factors for HCC development ranging from various toxins to …

Dendritic cells (DCs) are increasingly used as adjuvants for vaccination strategies; however,
there has been very little development in DC vaccines for patients with hepatocellular …

Interleukin‐33 (IL‐33), a cytokine with pleiotropic functions, is elevated in serum of patients
with hepatocellular carcinoma (HCC). This study investigated the effects of local IL‐33 …

Background: To date, no adjuvant treatment has been shown to have a clear benefit in
patients with hepatocellular carcinoma (HCC). In this prospective phase I/IIa study, we …

Objective: Signal transducer and activator of transcription 3 (STAT3) is activated in
hepatocellular carcinoma (HCC), and tumor-associated macrophage plays an important role …

Background: Hepatocellular carcinoma (HCC) is the 3rd most common cause of cancer-
related death worldwide. It has evolved different immune escape mechanisms, which might …